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Valentina Lorenzetti, Nadia Solowij, and Murat YücelABSTRACT
The past few decades have seen a marked change in the composition of commonly smoked cannabis. These
changes primarily involve an increase of the psychoactive compound Δ9-tetrahydrocannabinol (THC) and a decrease
of the potentially therapeutic compound cannabidiol (CBD). This altered composition of cannabis may be linked to
persistent neuroanatomic alterations typically seen in regular cannabis users. In this review, we summarize recent
ﬁndings from human structural neuroimaging investigations. We examine whether neuroanatomic alterations are 1)
consistently observed in samples of regular cannabis users, particularly in cannabinoid receptor–high areas, which
are vulnerable to the effects of high circulating levels of THC, and 2) associated either with greater levels of cannabis
use (e.g., higher dosage, longer duration, and earlier age of onset) or with distinct cannabinoid compounds (i.e., THC
and CBD). Across the 31 studies selected for inclusion in this review, neuroanatomic alterations emerged across
regions that are high in cannabinoid receptors (i.e., hippocampus, prefrontal cortex, amygdala, cerebellum). Greater
dose and earlier age of onset were associated with these alterations. Preliminary evidence shows that THC
exacerbates, whereas CBD protects from, such harmful effects. Methodologic differences in the quantiﬁcation of
levels of cannabis use prevent accurate assessment of cannabis exposure and direct comparison of ﬁndings across
studies. Consequently, the ﬁeld lacks large “consortium-style” data sets that can be used to develop reliable
neurobiological models of cannabis-related harm, recovery, and protection. To move the ﬁeld forward, we encourage
a coordinated approach and suggest the urgent development of consensus-based guidelines to accurately and
comprehensively quantify cannabis use and exposure in human studies.
Keywords: Cannabidiol, Cannabinoids, Cannabis, CBD, Hippocampus, Prefrontal, THCISShttp://dx.doi.org/10.1016/j.biopsych.2015.11.013Although cannabis has existed for thousands of years, the
past few decades have seen a marked increase in the
prevalence of highly potent cannabis strains (1). These strains
have a high proportion of the psychoactive constituent Δ9-
tetrahydrocannabinol (THC) (2), which exerts persistent
adverse effects on cognition, mental health, and the brain
(3,4). In parallel, there are decreasing levels of other constit-
uent cannabis compounds, such as cannabidiol (CBD), which
has been touted as a potential therapeutic agent for conditions
ranging from chronic pain and seizures to psychiatric symp-
toms (5–7). These recent changes in the composition of
“street” cannabis create a new and complex landscape for
investigators endeavoring to understand the neurobiological
harm and the therapeutic potential of cannabis products.
Speciﬁc cannabinoid compounds have distinct effects on
mental health and brain function. The psychoactive and
addictive properties of cannabis are primarily due to THC (8).
Increased availability of cannabis varieties that are high in THC
(e.g., “skunk”) have been consistently linked to accelerated
onset of psychosis (9,10), increased cannabis-related hospital
admissions (11), and increased anxiety symptoms and
psychotic-like experiences (12–15). Preclinical studies showed
that THC is neurotoxic to brain areas rich in cannabinoid type& 2016 Society of Biological Psychiatry. T
N: 0006-3223 B
SEE COMMENTA1 receptors, including the hippocampus (16–20), amygdala
(20), striatum (21), and prefrontal cortex (PFC) (21–23). In
contrast, CBD has been found to have anxiolytic, antipsy-
chotic, and therapeutic properties (24–27). There is evidence
suggesting that CBD is neuroprotective, mitigating the neuro-
toxic effects of THC (28–30).
The compounds THC and CBD have also been shown to
have opposing effects on the functional activity and connec-
tivity between brain regions that are high in cannabinoid
receptors, such as the hippocampus, amygdala, striatum,
cerebellum, and PFC (12–14,31–36). These changes in brain
function, documented using functional magnetic resonance
imaging (MRI), may modulate the effects of THC on anxiety
and psychotic-like experiences in humans (5,32,37). Similar
processes may underpin the protective effects of CBD on
such experiences (5,6,27,32,37). Participants pretreated with
CBD do not experience the psychotogenic and anxiogenic
effects of THC (12–14,32–37).
The recent changes in the relative composition of canna-
binoids found within commonly available cannabis increase
the potential for psychological and neurobiological harm in the
current generation of cannabis users. However, the relative
contribution of the two major compounds of cannabis (i.e.,his is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). e17
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PsychiatryTHC and CBD) to such damage is unclear (37). In this review,
we summarize the current literature on neuroanatomic alter-
ations reported in regular cannabis users, which includes nine
additional studies relative to the most recent review on the
topic, reﬂecting an increased focus on this ﬁeld of research
and warranting a need to integrate the most recent ﬁndings
(38–46). We present a novel focus on the emerging evidence
for differential roles of speciﬁc cannabinoids in neuroanatomic
abnormalities (41,43,47,48). First, we provide an overview of
ﬁndings and stratify them according to brain regions. Second,
we examine the link between neuroanatomic alterations and
levels of cannabis use, with a speciﬁc focus on the cannabi-
noid compounds THC and CBD. Finally, we identify major
limitations of current research, particularly in relation to the
measurement of cannabis use and cannabinoid compounds.
These methodologic inadequacies limit the ability to develop
evidence-based models of the effects of cannabis on neuro-
anatomy, whereby speciﬁc patterns (and types) of cannabis
use are associated with discrete alterations in deﬁned neural
circuits. We suggest that a coordinated approach is required
to move the ﬁeld forward, and we offer preliminary guidelines
to develop a standardized protocol to measure levels of
cannabis use.
METHODS AND MATERIALS
We performed a PubMed search on April 7, 2015, using the
keywords “Cannabis OR Marijuana” AND “MRI OR Computed
Tomography OR Neuroimaging” and identiﬁed 492 articles.
We screened these studies according to the following inclu-
sion criteria: 1) use of structural neuroimaging techniques and
2) examination of regular cannabis users (as deﬁned by each
study protocol). We excluded nonempirical studies and sam-
ples including any other regular substance use or major
psychopathologies. We included 32 studies in this review for
further inspection (30,38–46,49–70), of which 23 were
described previously (47). Nine additional studies conducted
since 2012 were identiﬁed (38–46). The newest studies add to
the literature ﬁve investigations of the PFC (38–42,44) and of
the hippocampus (39,40,44–46); four investigations of the
amygdala (39,41,44,46); three investigations of the striatum
(39,41,43); two investigations of the insula (40,41); and single
investigations of the parietal and occipital cortices (41),
cerebellum (39), and pituitary gland (38).
RESULTS
Characteristics of Samples Included in Structural
MRI Studies
Key characteristics of the reviewed samples are summarized
in Table 1 and Figure 1. The total sample sizes included
between 15 and 30 participants [range, 8 (63) to 62 (42) control
subjects and 10 (70) to 57 (65) cannabis users]. Mean ages of
cannabis users were between 17 years (49,54) and 40 years
(38,45,50,58). The age distribution varied within samples,
ranging from 16 years (49,54) to 60 years (38,45,50,58).
All samples of cannabis users smoked cannabis regularly,
on a daily (30,39,40,42–44,49,51,62,68–70) or almost daily
(38,41,45,50,53,55,58,61,63) basis. Some studies did not
provide information on frequency of use but estimated thee18 Biological Psychiatry April 1, 2016; 79:e17–e31 www.sobp.org/jonumber of smoking episodes (52,54,56,57,60,64) and joints
(38,45,50,58,59,65–67). Most cannabis users started smoking
between age 15 and 17 years. Participants in a few samples
started smoking 1 or 2 years earlier [14 years (43,52)] or later
[18–20 years (38,42,45,50,53,58,64)]. Duration of use varied
greatly across all examined samples and ranged from 2 years
(54,60) to 23 years (62,69) of regular use. Lifetime exposure to
cannabis was computed in cumulative number of joints, cones
(standard cannabis unit, with 1 joint = 3 cones, 1 g = 12
cones; for other conversions, see guidelines from the National
Cannabis Prevention and Information Centre at https://ncpic.
org.au/media/1593/timeline-followback.pdf) (red triangles in
Figure 2), or smoking episodes (blue squares in Figure 2),
which was available for all but a few studies (39,43,
64,66,67,69,70).
Lifetime episodes of cannabis use ranged from 402 (60) to
5625 (42). Lifetime cumulative cannabis dosage (dosage 3
smoking days 3 duration of regular use) ranged from 5322
cones (30) to 68,000 cones (68). Most studies measured
cannabinoid compounds, with three exceptions (39,55,62). In
20 studies, urinalysis was used to detect cannabinoid com-
pounds. Eight studies reported the levels of cannabinoid
metabolites. Mean values for 11-nor-9-carboxy-THC
(THC-COOH) (green circles in Figure 2) were reported from
toxicology analyses of urine samples in eight studies
(38,40,45,49,50,54,58) and analyses of hair samples in one
study (30). In 11 studies, positive [three studies (44,53,63,64)]
or negative [eight studies (51,56,57,59–61,65)] returns were
reported from toxicologic analysis of urine samples without
quantiﬁcation.
The reviewed studies used various specimens to detect
cannabinoids or their metabolites, including urine samples in
19 studies (30,38,40–43,45,49,50,52,54,56–60,63,64,71), oral
ﬂuid (40) and blood samples (40) in single studies, and hair in 2
studies (30,44), only one of which reported the outcome of the
assessment (30) (Table 1). Some studies used several speci-
mens [i.e., hair and urine (30,44), blood and oral ﬂuid (40)].
Breathalyzers were used in ﬁve studies to screen for acute
intoxication (52,56,57,59,60). Several studies controlled for
the confounding effects of alcohol (n = 18) and tobacco use
(n = 13) (Table 1) by covarying for their inﬂuence in group
comparisons or reanalyzing the data after excluding partici-
pants with concurrent alcohol and tobacco use.Neuroanatomic Alterations in Regular Cannabis
Users Relative to Control Subjects
Neuroanatomic alterations were reported in several brain
regions (Table 2 and Figure 3A). Abnormalities in cannabis
users, relative to control subjects, emerged most consistently
in the hippocampus [seven studies (30,40,45,51,58,63)]. Sev-
eral studies reported alterations in the volume (i.e., sum of all
voxels that are included within the boundaries of the region of
interest) and gray matter density (i.e., amounts of gray or white
matter concentration in each voxel) within the amygdala and
striatum (41,43,52,58,63), PFC (40–42,49,55,70), parietal cor-
tex (41,49,55), insular cortex (40,41,49), and cerebellum
(50,53,56). Single studies reported alterations within the fusi-
form gyrus (63), temporal pole, superior temporal gyrus, and
occipital cortex (41).urnal
Table 1. Sample Characteristics of Structural Magnetic Resonance Imaging Studies of Regular Cannabis Users
Study
Sample N
(Males)
Age
(Years) Cannabis Alcohol Tobacco
CB HC CB HC
Duration
(Years)
Age of
Onset
(Years)a Dosageb Frequencyc Specimens CB HC
Control
for CB HC
Control
for
Lorenzetti
et al., 2015
(38)
15 (15) 16
(16)
40
6
9
36
6
10
20 6 7 20 6 7 Ep./life.: 62,000; Cone/
past 1 year: 77,816 6
66,542; Cone/life.:
186,184 6 210,022
Days/month
28 6 5
Urine SD/week:
10 6 6
SD/week:
7 6 5
Yes (cov.) Cig./day:
17 6 9
Cig./day:
8 6 9
Yes (cov.)
Weiland et al.,
2015 (39)
29 (16) 29
(16)
28
6 7
27
6 7
— — — Daily — SD/month 7 6 3;
AUDIT 12 6 7
SD/month
7 6 3; AUDIT
12 6 8
Yes (cov.) Cig./day
11 6 8
Cig./day
8 6 8
Yes (cov.)
Battistella
et al., 2014
(40)d
Reg.: 25
(0)
— 23
6 2
— 7 6 3 16 6 2 — Occ./month
63 6 23
Urine, blood,
and oral
ﬂuid
SD/week 10 6 5 — Yes (regr.) — — —
Occ.: 22
(0)
25
6 2
8 6 3 17 6 2 Occ./month 462 SD/week 5 6 2
Filbey et al.,
2014 (42)
CB, toba-
cco,
alcohol:
48 (33)
62
(39)
28
6 8
30
6 8
10 6 8 18 6 3 Occ./week: 11 6 1;
Ep./life.e: 5,720
Almost daily — n 5 21 drinkers — Yes (excl.
users)
n 5 21
smokers
— Yes (excl.
users)
CB only
27 (17)
28
6 9
9 6 9 19 6 3 Occ./week: 11 6 1;
Ep./life.e: 5,148
No drinkers No smokers No smokers
Gilman et al.,
2014 (41)
20 (9) 20
(9)
21
6 2
21
6 2
6 6 3 17 6 2 Joints/week: 11 6 10;
Life. conee: 10,296
4 6 2 Urine SD/week 5 6 5;
AUDIT 6 6 2
SD/week
3 6 2; AUDIT
3 6 2
Yes (cov.) n 5 7 occ.;
n 5 1 daily
No smokers Yes (cov.)
Yip et al., 2014
(43)f
Abst. 21
days: 13
20
(0)
27
6 2
29
6 2
14 6 3 13 6 1 Ep./life.e: 2,688 Days/month 16
6 3
Urine Days/month 4 6
2; n 5 1 abuse;
n 5 4 past use
disorder
— No n 5 8 smokers n 5 2 smokers No
Current: 7 9 6 2 14 6 1 Ep./life.e: 3,840 Days/month 20
6 4
Days/month 3 6
1; n 5 0 abuse;
n 5 4 past use
disorder
n 5 7 smokers
Batalla et al.,
2013 (44)
29 (29) 28
(28)
21
6 2
22
6 3
6 6 2 15 6 1 Joints/day: 3 6 2; Joints/
life.: 5,203 6 4,192;
Cone/life.e: 15,609 6
12,576
Daily Hair, urine SD/week: 5 6 4;
Age onset: 16 6
2; duration
years: 6 6 2
SD/week: 3 6 3;
Age onset: 16 6
2; duration
years: 6 6 3
No n 5 27
smokers;
Cig./day:
6 6 5
n 5 9
smokers;
Cig./day:
2 6 6
No
Solowij et al.,
2013 (45)
15 (15) 16
(16)
40
6
9
36
6
10
20 6 7 20 6 7 Ep./life.: 62,000; Cone/
past 1 year: 77,816 6
66,542; Cone/life.:
186,184 6 210,022
Days/month 28
6 5
Urine SD/week: 10 6 6 SD/week: 7 6 5 Yes (cov.) Cig./day:
17 6 9
Cig./day:
8 6 9
Yes (cov.)
Schacht et al.,
2012 (46)
37 (14) 37
(14)
28
6 8
27
6 8
10 6 9 18 6 3 — 6 6 1 days/week — Days/month: 7 6
7; SD/drinking
day: 3 6 2
n 5 5 smokers Yes (cov.) Days/
month:
3 6 4; SD/
drinking day:
2 6 1
No smokers Yes (cov.)
McQueeny
et al., 2011
(52)
35 (27) 47
(36)
18
6 1
18
6 1
3; Abst. days: 28 14 Ep./life.: 446 12 ep./week; 10
hits/ep.
Urine,
Breathalyzer
Ep./life.: 24 6 44 Ep./life.: 212 6
175
Yes (cov.) FTND: 0 6 0 FTND:
0.2 6 .4
Yes (cov.)
Cousijn et al.,
2012 (53)
33 (12) 42
(16)
21
6 2
22
6 2
3 6 2 19 6 2 Grams/week: 3 6 2;
Joints/life.: 1580 6
1425; Cone/life.e: 4740
6 4725
5 6 2 days/week Urine AUDIT 6 6 3 AUDIT 5 6 3 Yes (regr.) FTND: 3 6 2;
Cig./day: 7 6
7; Duration: 4
6 4 years
FTND: 1 6 1;
Cig./day: 1 6
4; Duration:
1 6 2 years
Yes (cov.)
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Table 1. Continued
Study
Sample N
(Males)
Age
(Years) Cannabis Alcohol Tobacco
CB HC CB HC
Duration
(Years)
Age of
Onset
(Years)a Dosageb Frequencyc Specimens CB HC
Control
for CB HC
Control
for
Lopez-Larson
et al., 2011
(49)
18 (16) 18
(16)
17
6 1
17
6 8
Reg. use: 19 6 1;
Heavier use
(months):
19 6 14
16 6 1 Ep./week: 10 6 8;
Ep./life.: 1346 6 1372;
THC ng/mL:
455 6 352
Daily Urine n 5 3 drinks .
once/week
— No Occ./week: 10
6 4; Occ./life.:
1,346 6 1,371
— No
Solowij et al.,
2011 (50)
15 (15) 16
(16)
40
6
9
36
6
10
20 6 7 20 6 5 Cone/month: 636 6 565;
cone past 10 years:
77,816 6 66,542
28 6 5 Urine SD/week:
10 6 6
SD/week:
7 6 5
Yes (cov.) Cig./day:
17 6 9
Cig./day:
8 6 9
Yes (cov.)
Ashtari et al.,
2011 (51)
14 (14) 14
(14)
19
6
0.8
19
6
1
5 6 2; Abst.
months: 7
6 4
13 6 2 Daily joints: 6 6 3;
Joints/life.: 11,220;
Cone/life.e: 33,660
Daily — n 5 5 abuse Ep./life.: ,5 No n 5 8
abuse/
dependence
Ep./life.: ,5 No
Churchwell
et al., 2010
(54)
18 (16) 18
(12)
17
6 1
17
6 1
2e First try:
15 6 0.3;
Reg.:
16 6 0.2
Ep./life.: 1353 6 323;
Dose THC ng/mL:
429 6 85
Ep./week:
9 6 2
Hair, urine n 5 2 abuse — No n 5 4
current use
— No
Demirakca
et al., 2010
2011 (30)
11 (11) 13
(13)
22
6 2
23
6 2
5 16 6 2 Daily THC grams: 0.3;
Cone/life.e: 5322
Daily Urine Drinks/day 5 1.5 Drinks/day 5 0.3 Yes (cov.) n 5 6
smokers
n 5 1
smoker
Yes (cov.)
Mata et al.,
2010 (55)
30 (23) 44
(25)
26
6 5
26
6 6
8 6 9 17 6 4 Cone/week: 27 6 21;
Cone/life.: 11,619 6
9387
Almost daily — n 5 23
drinkers
n 5 23
drinkers
Yes (cov.) n 5 25
smokers
n 5 17
smokers
Yes (cov.)
Medina et al.,
2010 (56)
16 (12) 16
(10)
18
6 1
18
6 1
362; Abst.
days: 107
6 33
15e Ep./life.: 476 6 269 — Urine,
Breathalyzer
Ep./life.: 195 6
137
Ep./life.:
23 6 47
Yes (regr.) Cig./month: 29
6 74
Cig./month: 5
6 20
No
Medina et al.,
2009 (57)
16 (12) 16
(10)
18
6 1
18
6 1
3 6 2; Abst.
days: 107
6 33
15e Ep./life.: 476 6 269 — Urine,
Breathalyzer
Ep./life.: 230 6
128
Ep./life.:
25 6 51
Yes (cov.) Ep./life.: ,25 Ep./life.: ,5 No
Yücel et al.,
2008 (58)
15 (15) 16
(16)
40
6
9
36
6
10
20 6 7 20 6 7 Ep./life.: 62,000; Cone/
past 1 year: 77,816 6
66,542; Cone/life.:
186,184 6 210,022
Days/month 28
6 5
Urine SD/week:
10 6 6
SD/week:
7 6 5
Yes (regr.) Cig./day:
17 6 9
Cig./day:
8 6 9
Yes (regr.)
Medina et al.,
2007 (60)
26 (19) 21
(14)
18
6 1
18
6 1
2 yearse 15e Ep./life.: 402 6 260 Ep./month:
14 6 11
Urine,
Breathalyzer
Ep./life.:
152 6 185
Ep./life.:
8 6 16
Yes (cov.) n 5 9 smoked
past month;
Cig./day:
3 6 3
n 5 1 smoked
past month;
Cig./day: 1
No
Medina et al.,
2007 (59)
16 (12) 16
(11)
18
6 1
18
6 1
3 6 2; Abst.
days: 28
15e Ep./life.: 476 6 269 — Urine,
Breathalyzer
Ep./life.: 230 6
128
Ep./life.: 25 6 51 Yes (regr.) Ep./life.: ,25 Ep./life.: ,5 No
Jager et al.,
2007 (61)g
20 (13) 20
(13)
25
6 5
24
6 4
8 6 5 16e Joints/life. (median):
1900; Joints past 1 year
(median): 333
Almost daily — SD/week: 10 SD/week: 6 Yes (cov.) Cig./week: 10 Cig./week: 0 Yes (cov.)
Tzilos et al.,
2005 (62)
22 (16) 26
(19)
38
6 6
30
6 9
Reg.: 23 6 6;
Daily: 19 6 8
16 6 4 Ep./life.: 20,140 6 13,866 Daily — Drinks/life.: 6,524
6 5,934
— No Life. cig. packs:
2,727 6 2,981
— No
Matochik et al.,
2005 (63)
11 (11) 8
(8)
30
6 5
25
6 5
8 6 6; Abst.
days: 20
16 6 3 Joints/week: 35 6 18;
Cone/life.e: 40,599
Almost daily Urine SD/week: 2 6 2 SD/week: 1 6 2 No — — No
Block et al.,
2000 (64)
18 (8) 13
(6)
22
6 1
23
6 1
4 6 0.4 18e — Ep./week: 18 6 2 Urine Drinking days,
past month &
and 2 years:
6 6 1
Drinking days,
past month 4 6
1 & and past 2
years: 3 6 1
No — — No
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Table 1. Continued
Study
Sample N
(Males)
Age
(Years) Cannabis Alcohol Tobacco
CB HC CB HC
Duration
(Years)
Age of
Onset
(Years)a Dosageb Frequencyc Specimens CB HC
Control
for CB HC
Control
for
Wilson et al.,
2000 (65)
57 (25);
CB
onset:
early 16
(13), late
9 (19)
— 31
6 7
— R 5 11–26; Early
onset: 15 6 6;
Late onset: 14
6 7
17 6 4; Early
onset:
#17; late
onset:
.17
Joints/year; Early onset:
194 6 169; Late onset:
164 6 387
— — n 5 48 drinkers;
n 5 2 former
drinkers
— Yes (cov.) n 5 27
smokers;
n 5 3 former
smokers
— No
Hannerz and
Hindmarsh,
1983 (66)
12 (8) 12
(8)
26 26 10 — — — — — — — — — —
Kuehnle et al.,
1977 (67)
19 (19) 19
(19)
24 — Inward study: 5
days abst.; 21
days CB use; 5
abst. days
— — Outward monthly
joints: 35;
Inward study,
total joints: 111
— — — — — — —
Co et al., 1977
(68)
12 (12) 34
(34)
24 26 7 Occ.: 16;
Reg.: 17
— Joints/day: 9 — — — — — — —
Stefanis, 1976
(69)
47 (47) 40
(40)
40 42 23 — — Daily — — — — — — —
Campbell
et al., 1971
(70)
10 (10) 13
(7)
23 20 7 16 — Daily — — — — — — —
Values for all measures are mean (SD).
abst., abstinence; AUDIT, Acohol Use Disorder Identiﬁcation Test; CB, cannabis users or cannabis; cig., cigarettes; cone, standardized cannabis unit; cov., covariate; ep., episodes; excl.
users, excluded users with comorbid alcohol or tobacco use (or both); FTND, Fagerström Test for Nicotine Dependence scores; HC, healthy non–cannabis using control subjects; life., lifetime;
occ., occasional use; past 1 year, over the past 12 months; R, range; reg., regular cannabis use; regr., regressor; SD, standard deviation; THC, Δ9-tetrahydrocannabinol.
aAge of cannabis use initiation (occasional, regular, or heavy).
bMeasures of cannabis dosage (smoking episodes, cones, joints, grams).
cMeasures of cannabis use frequency (daily, weekly, monthly).
dFor Battistella et al. (40), median and median absolute deviation values are provided.
eEstimated values based on published data.
fFor Yip et al. (43), mean and SE values are provided.
gFor Jager et al. (61), mean values are provided.
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Figure 1. Summary of sample size, mean age, and mean cannabis use
characteristics of the samples included in structural magnetic resonance
imaging studies of cannabis users.
Cannabinoid Compounds and Neuroanatomy
Biological
PsychiatryOverall, neuroanatomical alterations included most consis-
tently 1) volumetric reductions in all regions, with the excep-
tion of the cerebellum and striatum, where larger volumes
were also observed (41,50,53); 2) higher gray matter density in
most regions (amygdala, PFC, parietal cortex, striatum), with
the exception of one study that found lower prefrontal gray
matter density in cannabis users relative to control subjects
(41)—this exception may result from noise or reﬂect a true
change demonstrating complex effects of cannabis on gray
matter density; 3) altered shape, sulcal-gyral anatomy; and 4)
cortical thickness (49). There is substantial overlap between
the location of the neuroanatomic alterations in cannabis users
(blue heat map, Figure 3A) and the location of high-density
concentration of cannabinoid type 1 receptors (green heat
map, Figure 3B) (31).
Most studies found abnormalities within the hippocampus,
which has a very high cannabinoid receptor density relative to
other brain regions [i.e., 1680 binding sites across all hippo-
campal subregions (31)]. Neuroanatomic abnormalities alsoe22 Biological Psychiatry April 1, 2016; 79:e17–e31 www.sobp.org/jowere found in prefrontal regions with very high densities of
cannabinoid receptors [i.e., 627 and 518 binding sites within
the lateral PFC and anterior cingulate cortex, respectively (31)].
Also, the amygdala and cerebellum, brain regions that show
consistent abnormalities, have a high density of cannabinoid
receptors [i.e., 102 and 137 binding sites, respectively (31)].
There appears to be an intriguing link between the concen-
tration of cannabinoid receptor density in the brain and the
consistency with which studies detect abnormal neuroanat-
omy in regular cannabis users.
Associations With Levels of Cannabis Use
The link between neuroanatomy and cannabis use levels was
examined in 21 studies (Figure 4) (30,38–42,44,45,49–55,
57,58,62–65). Cannabis dosage was most consistently asso-
ciated with the neuroanatomy of the hippocampus (30,51,
53,58) and PFC (44,49,57) and less consistently with the
neuroanatomy of the amygdala, striatum (41), parahippocam-
pal gyrus, insula, and temporal pole (40). Age of onset was
most consistently associated with prefrontal neuroanatomy
(49,54) and less consistently with the neuroanatomy of the
parahippocampal gyrus, temporal cortex (40), and global brain
measures (49). Duration of regular use was associated with the
neuroanatomy of the PFC (57) and hippocampus (63) but not
with the neuroanatomy of the amygdala (51), parahippocampal
gyrus (40,44,63), cerebellum (44,52), and striatum (41). Most
studies did not examine the association between cannabis use
measures and neuroanatomy (Figure 4).
Associations Between Quantiﬁed Cannabinoid
Levels and Neuroanatomy
Five studies examined the link between quantiﬁed cannabinoid
levels and the neuroanatomy of the hippocampus (30,45,58),
PFC (38,49), and amygdala (58) as well as the cerebellum in a
sixth additional study [cited by Lorenzetti et al. (48)]. Four
studies found signiﬁcant associations (30,49).
Demirakca et al. (30) found a signiﬁcant association
between higher ratio of THC/CBD (but not THC, measured
as ng/mg hair, mean .31 ng/mg, SD .2 ng/mg) and smallerFigure 2. Summary of reviewed
samples’ lifetime cumulative dosage
[red triangles (30,41,43,46,48,49,
51,53,56,59,61,63,66,69)], computed
as cones according to guidelines
(https://ncpic.org.au/media/1593/time
line-followback.pdf); smoking epi-
sodes [blue squares (44,45,47,50,
52,54,55,57,58)], and measured levels
of Δ9-tetrahydrocannabinol metabo-
lite [11-nor-9-carboxy-THC, ng/L (45)
or ng/mg (30,43,46–48,52,56)] from
urine toxicology (green circles) and
hair [orange rhombus, reﬂecting 3
months of exposure (30)].
urnal
Table 2. Neuroanatomical Alterations in Regular Cannabis Users by Brain Region
Brain Region/Study
Volume
Gray Matter Density Gyriﬁcation Thickness Shape% Change Cohen’s da
Hippocampus
Battistella et al., 2014 (40) ↓ NA .1 — — — —
Solowij et al., 2013 (45) — NA NA — — — Altered
Schacht et al., 2012 (46) ↓ 26% 0.7 — — — —
Demirakca et al., 2011 (30) ↓ NA — — — — —
Ashtari et al., 2011 (51) ↓ 213% 1.3 — — — —
Yücel et al., 2008 (58) ↓ 212% 1.2 — — — —
Matochik et al., 2005 (63) ↓ NA NA — — — —
Amygdala
Gilman et al., 2014 (41) — NA NA ↑ — — Altered
Yücel et al., 2008 (58) ↓ 27% 0.9 — — — —
Schacht et al., 2012 (46) ↓ 25% 0.5 — — — —
Striatum/Thalamus
Accumbens
Gilman et al., 2014 (41) ↑ NA NA ↑ — — Altered
Caudate
Yip et al., 2014 (43) ↓ NA NA — — — —
Thalamus
Matochik et al., 2005 (63) — NA NA ↑ — — —
Prefrontal Cortex
OFC
Filbey et al., 2014 (42) ↓ NA NA — — — —
Battistella et al., 2014 (40) ↓ NA NA — — — —
Medial frontal gyrus
Gilman et al., 2014 (41) — NA NA ↑ ↓ — — —
DLPFC, frontal pole
Gilman et al., 2014 (41) — NA NA ↓ — — —
PFC
Mata et al., 2010 (55) — NA NA — Altered — —
Campbell et al., 1971 (70) — NA NA — Altered — —
Caudal middle, superior frontal
Lopez-Larson et al., 2011 (49) — NA NA — — ↓ —
Parietal Cortex
Precuneus, postcentral
Gilman et al., 2014 (41) — NA NA ↑ — — —
Parietal, paracentral
Matochik et al., 2005 (63) — NA NA ↑ — — —
Inferior parietal, lingual, paracentral gyri
Lopez-Larson et al., 2011 (49) — NA NA — Altered ↓ —
Parietal
Mata et al., 2010 (55) — NA NA — Flatter sulci — —
Insula
Gilman et al., 2014 (41) — NA NA ↑ — — —
Battistella et al., 2014 (40) ↓ NA NA NA — — —
Lopez et al., 2011 (49) — NA NA — — ↓ —
Cerebellum
Medina et al., 2010 (56) ↓ 17% 0.7 — — — —
Solowij et al., 2011 (50) ↑ 227% 21.6 — — — —
Cousijn et al., 2012 (53) ↑ 120% 0.6 — — — —
DLPFC, dorsolateral prefrontal cortex; NA, not applicable; OFC, orbitofrontal cortex; PFC, prefrontal cortex; ↑, cannabis users > control
subjects; ↓, cannabis users , control subjects; —, not measured or lack of signiﬁcant difference between cannabis users and control subjects.
aCohen’s d, measure of effect size, with medium effect size ranging between d = .5 and .8 and large effect size d > .9.
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Figure 3. Weighted color maps. (A)
Neuroanatomical alterations in canna-
bis users (blue-green), relative to con-
trol subjects (two to six studies). (B)
Brain map with regional distribution of
cannabinoid receptor density [dark-
light green; range, 40–1680 density
of receptor binding sites, measured
via autoradiographic techniques (3)].
Lighter colors indicate evidence from
more studies and greater density of
receptors. (C) Binary map (red) illus-
trates overlap between (A) and (B),
including regions high in cannabinoid
receptors that also show neuroanato-
mical alterations. (D) Binary map (vio-
let) illustrates nonoverlap between (A)
and (B), including areas that showed
neuroanatomic alterations and are low
in cannabinoid receptors.
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matter concentration. A similar ﬁnding was reported in a
separate sample of cannabis users with reduced hippocampal
volume relative to controls (72); a subgroup of users with high
levels of THC (and no detectable levels of CBD) in hair showed
more marked reductions relative to control subjects than the
other users, who had detectable levels of THC and CBD (72).
Two studies examined the association between prefrontal
neuroanatomy and urinary THC metabolite levels (38,49), with
one ﬁnding being a signiﬁcant association between higher
levels of THC-COOH (mean 455 mg/mL, SD 352 mg/mL) and
the thickness of prefrontal (and parietal) cortices (49). In light of
ﬁndings suggesting a role for THC metabolites in neuro-
anatomic alterations, N. Solowij, Ph.D., et al. (personal com-
munication, April 2015) re-examined a data set on cerebellar
neuroanatomy (50). They found that higher levels of THC-
COOH in urine measured the night before (Spearman ρ 5
2.577, p 5 .049) and on the day of the MRI scan (Spearman
ρ 5 2.790, p 5 .002) (Figure 5, left plot) were associated with
reduced cerebellar gray matter in cannabis users. The latter
relationship was strengthened with the removal of threee24 Biological Psychiatry April 1, 2016; 79:e17–e31 www.sobp.org/jocannabis users with very high levels of urinary cannabinoid
metabolites (Spearman ρ5 2.87, p5 .002) (Figure 5, right plot).
Only one study examined the link between CBD and
neuroanatomy in cannabis users (30). The CBD levels (ng/mg
hair, mean .13 ng/mg, SD .12 ng/mg) were associated with
higher hippocampal gray matter concentration (but not vol-
ume). Similarly, we recently found that cannabis users with
high levels of CBD showed no hippocampal volume abnor-
malities [i.e., were comparable to control subjects (72)]. In
contrast, the whole group of cannabis users, particularly users
with high THC and no detectable levels of CBD, showed
signiﬁcant hippocampal reductions relative to control subjects
(72).DISCUSSION
The reviewed literature demonstrates that regular exposure to
cannabis is associated with neuroanatomic alterations in
several brain regions, most consistently within the hippo-
campus (reduced volumes and gray matter density, altered
shape), followed by the amygdala and striatum, orbitofrontalurnal
Figure 4. Percentage of studies reporting associations between regional
neuroanatomy and cannabis use measures. Signiﬁcant associations (red),
nonsigniﬁcant associations (n.s.; blue), and associations unexamined (gray).
Amyg, amygdala; Hipp, hippocampus; Para-hipp, parahippocampal gyrus;
PFC, prefrontal cortex.
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associations emerged between higher cannabis dosage and
hippocampal alterations and between earlier age of onset andBiologicalPFC alterations. These trends (i.e., hippocampal volumetric
reduction) were previously observed (47), although there is
now increasing evidence for alteration within other regions
(i.e., striatum, orbitofrontal cortx, parietal cortex, insular cortex,
cerebellum). There was also preliminary evidence that neuro-
anatomic alterations within the hippocampus, cerebellum,
prefrontal, and lingual regions were associated with THC and
CBD levels speciﬁcally, suggestive of an adverse effect of THC
and a protective effect of CBD (from THC-related damage).
Neuroanatomic abnormalities were most reliably found in
regions that have a high concentration of cannabinoid type 1
receptors, to which THC binds to exert its psychoactive
effects (31). Cannabis plants that are typically used for drug
production have high levels of THC (17%–20%) (73) but low
levels of CBD (1). According to preclinical ﬁndings, THC
accumulates in neurons (74) and with chronic exposure
becomes neurotoxic (18). Neuroanatomic abnormalities may
result from the adverse effects of direct and chronic exposure
to high levels of THC found in commonly available “street”
cannabis. Although CBD may be neuroprotective (24,25) and
mitigate the adverse effects of THC (47,85), it is seldom found
in high levels (1). As one of the regions of highest density of
cannabinoid type 1 receptors (3), damage to the hippocampus
may be related to THC-induced neurotoxicity.
Putative Mechanisms
Neuroanatomic alterations in areas that are high or low in
cannabinoid receptors may result from distinct mechanisms.
Alterations within regions high in cannabinoid type 1 receptors
(hippocampus, amygdala, cerebellum, anterior cingulate cor-
tex) may involve 1) accumulation of THC and its metabolites in
neurons (74) that leads to THC-induced neurotoxicity [e.g.,
shrinkage of neuronal cell nuclei and bodies (19,20), reduced
synapse number (20), and reduced pyramidal cell density
(16,76)]; 2) downregulation, adaptation, and molecular and
signaling changes downstream of cannabinoid receptors
(77–82); and 3) changes in vascularity, and reductions in glia
and neuronal dendrites, which are associated with gray matter
volumes (83–85).
Chronic cannabinoid-induced alterations of neural oscilla-
tions in cannabinoid receptor–high regions [i.e., shown in
preclinical studies of the hippocampus (86,87) and amygdala
(88,89)] may propagate (90) to functionally and structurallyFigure 5. Association between
urinary 11-nor-9-carboxy-THC (THC-
COOH; ng/mg) (x axis) and cerebellar
gray matter volume (mm3) (y axis)
before (left) and after removal of three
outliers (right).
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cortex (91–93) and orbitofrontal cortex (94)] and lead to
neuroanatomic alterations of the latter. Previous studies in
neurodegenerative disorders showed a direct link between
alteration of connectivity (i.e., synchrony of activity) between
functionally and structurally related regions and alteration of
gray matter volumes in the same areas (95). Cannabis users
show impaired functional (34,96) and structural (97) connec-
tivity between cannabinoid receptor–high regions (i.e., hippo-
campus) and cannabinoid receptor–low regions (i.e., parietal
cortex, inferior frontal gyrus). In this review, cannabis users
showed neuroanatomic alterations in both regions. These
regions are integral components of the brain reward (98),
memory (99), and executive-attention systems (100,101) and
may mediate the deﬁcits that cannabis users show in these
domains (93,98,99–104).
The compound CBD may counteract THC-induced damage
to neuroanatomy, as it has been shown to alleviate neuro-
degeneration, reverse brain ischemic damage in mice (24), and
modulate the effects of THC by blocking cannabinoid type 1
receptors (105–107). The molecular mechanisms by which
CBD counteracts the effects of THC are unclear (24,105). It
may be that CBD, via attenuating THC-induced effects on
brain function (13,14,34,36), prevents the onset of molecular
mechanisms that would trigger neurotoxicity and lead to
neuroanatomic abnormalities in cannabis users. Multimodal
imaging studies in cannabis users that carefully examine levels
of THC and CBD (prior proportional exposure from hair
analysis and circulating levels in urine, blood, and oral ﬂuid
samples) would help elucidate the potential neurotoxic, neuro-
adaptive, or neuroprotective mechanisms involving different
cannabinoids.
Limitations of Reviewed Literature
There are major gaps in the measurement of cannabinoids and
cannabis use levels [e.g., dose, duration, frequency, age of
onset (47,75,108)]. The development of standardized methods
to characterize cannabis users and to identify the effects of
speciﬁc cannabinoids on the brain is warranted.
Measurement of Cannabinoid Levels. Hypotheses and
interpretation concerning neuroanatomic alterations in canna-
bis users often postulate that THC drives these effects.
However, few studies have tested this model directly by
obtaining quantiﬁed measures of THC-speciﬁc exposure.
Quantifying cannabinoid levels in hair could provide levels of
THC and CBD to which cannabis users have been exposed
cumulatively over a few months (109,110). Also, metabolites in
blood or urine measure circulating cannabinoids, which reﬂect
exposure over recent hours, days, or weeks, and, in daily or
near-daily users, indicate typically circulating levels. Although
methods exist for quantifying cannabinoid exposure, such
indices are underreported. The role of cannabinoid com-
pounds in causally driving neuroanatomic alterations in can-
nabis users cannot be ascertained.
Improvements in the time frame and reliability of toxicology
tests are warranted (111). For example, hair analyses inform
the past 3 months of exposure and rely on length of hair
available (1 cm of hair 5 1 month of exposure), which moste26 Biological Psychiatry April 1, 2016; 79:e17–e31 www.sobp.org/jo(but not all) participants can provide (109,110). We need better
reliability and validity studies for toxicology analyses, as there
is limited and contradictory evidence on this topic [e.g., urine
toxicology tests may not match positive self-reports of
cannabis use (111)]. Development of further measures of
cannabinoid metabolites that enable more reliable detection
of CBD in urine and other relevant cannabinoid metabolites
that have longer time windows may help in the objective
measurement of cannabinoid exposure. Finally, cannabinoid
compounds from specimens collected from participants may
not be stable over time (e.g., use of different varieties, breeds,
or parts of the cannabis plant). Although it would be difﬁcult to
systematically control for this, assaying cannabinoid content
from specimens, particularly in prospective studies, may
inform future work on their neurobiological impact.
Underreporting Key Aspects of Cannabis Use. Key
aspects of cannabis use are often not measured or reported,
including the 1) type of cannabis predominantly used by the
sample, the potency of which varies between marijuana
[1%–20% THC (1)], hashish (10%), and hashish oils [up
to 50% (112)]; 2) use of tobacco in cannabis preparations,
which can almost double the release of THC compared with
smoking pure cannabis (113); and 3) usual dosage and days of
use, age of onset of regular use, and problems associated with
use (114). The underreporting of levels of exposure limits our
understanding of the effects of cannabis use levels on the
human brain.Noisy Measurements. Measuring levels of cannabis use is
an inherently difﬁcult task. Self-reported levels of use are
compromised by retrospective accounts including difﬁculties
in remembering changes in use over the years, which are
exacerbated by memory deﬁcits in cannabis users (102,
115–117). Studies measure differently levels of cannabis
dosage (e.g., joints, smoking occasions, grams), frequency
(e.g., smoking either occasions or days), and age of onset
(e.g., of either ﬁrst try or of regular use). Levels of use are
estimated over distinct time windows (i.e., “usual” use; past 1–
6 months, past 1 year, 10 years, lifetime), and duration and
cumulative exposure measures often do not account for
periods of prolonged abstinence. These issues prevent a
direct comparison of ﬁndings across studies.Lack of a Comprehensive Tool. No single instrument
captures all key aspects of exposure to cannabis use and
cannabinoids (Table 3). Research groups often develop their
own in-house tools, which are not validated and standardized
to perform accurate measurements of the history of use [e.g.,
periods of prolonged abstinence or of heavier use (50,58)]. The
studies reviewed employed different instruments (114), obvi-
ating direct comparisons in the level of use across the
reviewed samples. Methodologic issues in measuring canna-
bis use preclude the development of evidence-based neuro-
biological models of cannabis-related harm in humans, which
rely on preclinical evidence (130,131) that cannot be replicated
in humans, given the interspecies differences in neuroanatomy
(132) and different routes of administration in animal studiesurnal
Table 3. Measurement of Cannabis Use Levels and Problems
Patterns of
Use Outcome Measures Instruments Period Over Which Measured
Type Marijuana, hashish, cannabis oils, spice, mixed
with tobacco
In-house, DSM, CUDIT,
CAST
Currently or usually (no detail about period over which it is
measured), not measured
Quantity
(how
much)
Number of grams, joints, bongs, blunts,
standard cannabis units (NCPIC guidelines)
Self-reported Cumulative (accumulated over a speciﬁed period of time) or average
(divided by a given period of time)
In-house, NCPIC
guidelines, CUDIT,
CDDR
Currently or usually (no detail about period over which it is
measured), monthly or past month, yearly or past year, past 10
years, lifetime
THC, THC-COOH, CBD, (quantiﬁed levels,
positive vs. negative outcomes)
Toxicology tests from: Detection windows, for smoked cannabis (118):
Hair 90 days (109,110)
Urine Single dose, 1.5–4 days; Chronic use, up to 2 weeks and longer
.25 days (119)
Oral ﬂuid 1–4 hours, also up to 16 hours (120)
Blood or plasma 20–57 hours (occasional), 3–13 days (regular users)
Breathalyzer 2 minutes, up to 12 hours (121)
Frequency
(how
often)
Days per week, per month; Occasions per day,
per week
In-house, NCPIC
guidelines, CUDIT
Usually, past month, past year, past 10 years, lifetime
Duration
(how
long)
Current age minus age of ﬁrst use; age of
regular use; prolonged abstinence periods
In-house, NCPIC
guidelines, CUDIT
Lifetime
Age of
onset
Regular use, ﬁrst use In-house, CUDIT,
CDDR, ASI
Lifetime
Problem
use
Cannabis use disorder diagnosis, severity,
symptoms
DSM (122,123) Past 6 months, and if endorsed in the past
Severity of problem use, addiction and
dependence
In-house semi-
structured interviews
(38,45,50,58)
Lifetime
CDDR (adolescents),
ASI
Lifetime, past 3 months
CAST Lifetime, past 30 days
CUDIT, SAS of the MINI Past 6 months
SDS Past 3 months
Withdrawal symptoms MWCL Since last use
ASI, Addiction Severity Index (127); CAST, Cannabis Abuse Screening Test (125); CBD, cannabidiol; CDDR, Customary Drinking and Drug Use
Record (126); CUDIT, Cannabis Use Disorder Identiﬁcation Test (124); MWCL, Marijuana Withdrawal Checklist; NCPIC, National Cannabis
Prevention and Intervention Centre guidelines (available from https://ncpic.org.au/media/1593/timeline-followback.pdf); SAS of the MINI,
Substance Abuse Scales of the Mini International Neuropsychiatric Interview of the DSM (128); THC, Δ9-tetrahydrocannabinol; THC-COOH,
11-nor-9-carboxy-THC; SDS, Severity of Dependence Scale (129).
Table 4. Recommended Set of Minimum Criteria
Type of cannabis used and whether it is mixed with tobacco
Ages of onset of ﬁrst use and of regular use
Recent (i.e., past month) and lifetime levels of use
Duration of regular use, accounting for prolonged abstinence periods
Standardized dosage measure (e.g., https://ncpic.org.au/media/1593/timeline-followback.pdf)
Cumulative dosage—accounting for periods of prolonged abstinence, and increases/decreases in dosage and smoking days
Cannabis use disorder severity, determined with Cannabis Use Disorders module of the DSM-5 (123)
Severity of dependence and problem use [e.g., Cannabis Use Disorder Identiﬁcation Test (124), Addiction Severity Index (127)]
Use of interview techniques that aid memory of past events [e.g., TimeLine Follow Back procedure (134)]
Toxicology tests—Breathalyzer, and urine and hair toxicology analyses to assess recent use and measure cannabinoids in the few weeks before assessment
Assay of samples brought by the participant would provide information on the cannabinoid composition of at least recent exposure (135,136)a
Measure key confounders associated with cannabis use [e.g., alcohol use with the Alcohol Use Disorder Identiﬁcation Test (137), and tobacco use with the
Fagerströom Tolerance Questionnaire (138)]
aWhile ideal, this raises ethical/legal challenges that need further consideration.
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cannabis smoke or vapors, variable doses), which create
different models of metabolizing THC (76).
We propose the development of internationally agreed-on
standards for quantifying exposure levels as a necessary step
to develop evidence-based neurobiological models of canna-
bis use. The platform PhenX Toolkit previously took steps in
this direction to improve the standard of research in substance
use (133). In this review, we incorporate these useful guide-
lines (i.e., lifetime/recent use, age of onset, diagnostic assess-
ment for problem use) and include additional items that are
speciﬁc to cannabis use research. Table 4 lists recommended
criteria for assessing regular cannabis use as a starting point
for further discussion and consensus around improving stand-
ardization of measurements within the international community
of cannabis researchers. We acknowledge that it will prove
difﬁcult, if not impossible, to determine the exact amount of
THC that cannabis users may be exposed to over signiﬁcantly
varying periods of time and drug availabilities. However, an
attempt at a more standardized approach is necessary to
isolate factors that may cause brain alterations.
CONCLUSIONS
Regular cannabis users show abnormalities within brain
regions that are high in cannabinoid type 1 receptors, partic-
ularly the hippocampus and the PFC. These abnormalities are
associated with higher levels of cannabis use (dosage, age of
onset, duration). The psychoactive compound THC may be
responsible for neuroanatomic damage in cannabis users,
whereas the potentially therapeutic compound CBD may
protect from such damage. Further evidence is needed to
verify this hypothesis. To develop evidence-based neurobio-
logical models of cannabis-related harm, objective measure-
ment of cannabinoid compounds and the development of
standardized measures of levels of cannabis use are neces-
sary next steps. Objective measurements also need to keep
up to date with the continually changing cannabinoid com-
pounds (e.g., CP-55940, WIN) in increasingly available syn-
thetic cannabinoids [e.g., K2, Spice (139)], which mimic the
psychoactive effects of THC, causing signiﬁcant mental health
harm (140,141) and unknown effects on the brain.
The mechanisms by which distinct cannabinoid compounds
harm (and beneﬁt) the brain are unclear. Research on the neuro-
biology of cannabinoids is not keeping up to date with ongoing
public policy debates on the legalization as well as the therapeutic
potential of the drug. To bridge this gap, we urgently need to
develop standardized measurements of cannabis use levels and
evidence-based neurobiological models of cannabinoid exposure.
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